CTLA4 and non-small cell lung carcinoma: In a randomized phase III clinical trial, the incidences of any-grade and high-grade CIP in NSCLC patients receiving durvalumab plus tremelimumab, a CTLA-4 inhibitor, were higher than those with durvalumab monotherapy (6.7% vs. 2.2% for any-grade CIP and 2.2% vs. 1.1% for high-grade CIP) (27).